New Delhi,  Reliance, a responsible organisation, leveraged its intellectual capital to contribute to the countrys fight against Covid-19.

Reliance's scientists analysed more than 1,000 genomes of the virus.

The knowledge base was used to develop novel cost-effective diagnostic kits called 'R-Green' and 'R-Green pro one'. These kits have received ICMR approval and showed a high degree of accuracy and specificity during validation studies.

Reliance has also collaborated with IIIM-CSIR (Jammu) to develop an RT-LAMP Kit to facilitate the point-of-care diagnosis of Covid-19.

The R&D team actively contributes to the company's technical wisdom to facilitate innovation globally by publishing research articles on diagnostics and treatment. Application of natural-astaxanthin for COVID-19 management published in 'Biomedicine and Pharmacotherapy' journal is recognised as top 100 research paper. The paper is listed in WHO's global repository.

PSA based oxygen concentrators can produce oxygen with 93 per cent (+- 3 per cent) purity. The unit is an excellent solution during hospitalisation situation due to Covid-19 to maintain the SpO2 level of a patient. Reliance R&D has designed oxygen generator with a purity of 90 per cent to 95 per cent with 5 LPM oxygen leveraging its expertise in adsorption technology.

Reliance collaborated with India's CSIR-National Chemical Laboratory (CSIR-NCL) to recycle Covid-19 PPE waste. Useful products such as automotive components and flowerpots are being made from the recycled PPEs.

Reliance Industries Limited issued its Annual Report for FY22 on August 6. The company will be holding its Annual General Meeting on August 29.

Among other things, the RIL Annual Report mentioned about the progress made by all its business verticals viz. Retail, Digital Services, O2C and E&P, and spoke about RIL's intentions in the Green Energy field.